Assess whether to resubmit, meet, or pause the program (b153f2)

SITUATION Clinical and Evidence Strategy work in a labeling team facing a boxed-warning debate now turns on to resubmit, meet, or because an FAERS cluster in a demographic the trials under-enrolled put CMC comparability package for a site change in play. Regulatory-affairs lead should say what CMC comparability package for a site change proves.

DECISION Regulatory-affairs lead in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. An FAERS cluster in a demographic the trials under-enrolled is noise around an already-controlled Clinical and Evidence Strategy process in a labeling team facing a boxed-warning debate, given CMC comparability package for a site change. 2. An FAERS cluster in a demographic the trials under-enrolled is the event in CMC comparability package for a site change that forces To resubmit, meet, for regulatory-affairs lead under Pharma & Life Sciences. 3. CMC comparability package for a site change shows a one-file miss after an FAERS cluster in a demographic the trials under-enrolled, not a Clinical and Evidence Strategy program failure. 4. CMC comparability package for a site change cannot decide to resubmit, meet, or yet after an FAERS cluster in a demographic the trials under-enrolled; hold is the only Pharma & Life Sciences close a labeling team facing a boxed-warning debate can defend.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether CMC comparability package for a site change supports the labeled claim regulatory-affairs lead would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read CMC comparability package for a site change against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled). The follow-on Clinical and Evidence Strategy action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in CMC comparability package for a site change, then the action for regulatory-affairs lead - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Missing page in CMC comparability package for a site change after an FAERS cluster in a demographic the trials under-enrolled, if any - Regulatory or exam hook Clinical and Evidence Strategy would cite